Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 27;13:20406207221093980. doi: 10.1177/20406207221093980

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2022

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 4. — Best response to zanubrutinib monotherapy in evaluable patients with treatment-naive CLL and 17p deletion in the SEQUOIA (BGB-3111-304) trial. ORR was defined as CR + CRi + PR + PR-L.

CLL, chronic lymphocytic leukemia; CR, complete response; CRi, CR with incomplete hematologic recovery; PD, progressive disease; PR, partial response; PR-L, PR with lymphocytosis; SD, stable disease.